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Abstract Long interspersed nuclear element 1 (L1)
belongs to a family of retrotransposons. Expression of the
normally repressed L1 retrotransposons has been shown to
induce genome instability by creating DNA double-stran-
ded breaks and chromosomal rearrangements through the
process of retrotransposition. At present, little is known
about the expression of L1-encoded ORF1p and ORF2p
which are indispensable for its retrotransposition activity.
Given its potentially harmful effects on the genome, we
investigated the implications of both ORF1p and ORF2p
expression and their subcellular localization in a range of
breast cancer cell lines and breast tumor tissues including
15 normal breast tissues, 25 fibroadenomas, 25 ductal
carcinomas in situ (DCIS), and 95 invasive cancers. Clin-
icopathologic parameters and survival outcomes were
investigated in association with the cytoplasmic and
nuclear expression of ORF1p and ORF2p using univariate
and multivariate analysis. High cytoplasmic expression of
ORF1p and ORF2p was seen in DCIS tumors, but they
were not related with survival outcome. The majority of
invasive cancers were found to express both ORF1p and
ORF2p in the cytoplasm, while nuclear expression was also
seen in a subclass of those invasive cancers in the range of
28–31 %. Tumors with high nuclear expression of ORF1p
and ORF2p were more significantly associated with lymph
node metastasis (p = 0.001) and the worst patient survival
(p \ 0.0001) than those with cytoplasmic expression. This
is the first study examining the effects of both ORF1p and
ORF2p expression in breast cancer tissues. Our observation
shows altered expression patterns of ORF1p and ORF2p
within invasive cancers, which are related to differences in
overall patient survival. The differing patterns of both
cytoplasmic and nuclear ORF1p and ORF2p expression
indicate that further studies of the biology and function of
L1 retrotransposons are required in breast cancer.
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Introduction
Breast cancer is challenging as it is a group of quite diverse
biologies—a great deal of molecular events occur with
these carcinomas and differ in profile between subtypes
therein. Tumors develop under the influence of both
genetic and epigenetic changes. It has been suggested that
epigenetic changes are more frequent in cancer cells than
genetic mutations [1]. Alterations of DNA methylation
patterns are a common feature of epigenetic change that
results in aberrant gene expression. During tumorigenesis,
cells undergo both genome-wide DNA hypomethylation
and local hypermethylation of CpG islands associated
with promoters [2]. Hypomethylation of long interspersed
nuclear element 1 (LINE-1 or L1) sequences occurs at a
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very early stage of malignant transformation, resulting in
inappropriate expressions of L1 retrotransposons [3, 4].
Indeed, the majority of DNA methylation studies have used
L1 retrotransposon’s expression as an indicator of the
methylation status of genome [5]. It was recently reported
that the hypomethylation of L1 retrotransposons activates
an antisense promoter for cancer-specific genes in human
cells [6].
About 20 % of the human genomes are made up of L1
retrotransposons, which are capable of reverse transcribing
their own mRNAs and inserting DNA copies into new
places within the genome [7]. While most of the copies of
L1s are defective because of truncations or mutations, the
human-specific (L1Hs) subfamily, which contains intact,
full-length L1 elements, is still potentially active in the
human genome [8]. At present, at least 100 copies of L1Hs
have been identified as functional elements, retaining their
ability to move about the genome, i.e., retrotransposition
competent [9]. An active L1 retrotransposon is composed
of the 50-untranslated region (50-UTR), which harbors an
internal promoter, two open reading frames, and the 30-
UTR which includes a poly-A tail. L1 encodes two pro-
teins: a 40-kDa protein (ORF1p) with RNA-binding
activity [10], and a 150-kDa protein (ORF2p) with critical
endonuclease and reverse transcriptase activities [11, 12].
ORF2p cuts genomic DNA to provide a 30-end primer from
which the L1 mRNA is copied into DNA. An insertion is
then made at this new genomic site, resulting in a newly
retrotransposed L1 DNA copy. These L1 insertions are
capable of altering the genome in myriad ways by dis-
rupting genes, altering splicing, increasing the frequency of
recombination, and negatively affecting the stability and
integrity of the genome because of their ability to create
breaks in genomic DNA during the process of mobilization
or retrotransposition [13–15].
A recent study surveying lung tumors and comparing
their genomes against their adjacent normal tissues dem-
onstrated that tumors exhibit high frequencies of L1 ret-
rotransposition activity that are not present in the normal
tissues [16]. These findings indicate that, in principle, L1
expression has the potential to contribute to genomic
instability. Because of the potential harmful impact of L1
activity, it is believed that L1 expression is held in check
by a variety of genome defense mechanisms [17, 18]. L1
expression is undetectable in the majority of normal cells,
and thus the detection of overexpression of L1 retrotrans-
posons may serve as an indicator of unstable genome. At
present, little is known about the L1 expression pattern.
Given that the L1 retrotransposition could induce genome
instability, we set out to characterize the expression pat-
terns of both ORF1p and ORF2p at various stages of breast
cancer and to determine whether the expression pattern
might be of clinical usefulness.
Materials and methods
Cell cultures
Normal human breast epithelial cells (HMEC) and mam-
mary epithelial growth medium (MEGM Bullet kit) were
obtained from Lonza (Walkersville, MD). The HMEC
(Lonza-CC-2551) and immortalized non-tumorigenic
MCF10A cells (ATCC-CRL-10371) were cultured using
the MEGM Bullet kit supplemented with 10 lg/ml of
insulin. The T47D, SKBR3, BT-20, MDA-MB-361, MCF-
7, Hs578T, MDA-MB-231, and MDA-MB-436 cell lines
were obtained from ATCC and cultured in Dulbecco’s
modified Eagle’s medium with 2 mM L-glutamine and
10 % FCS at 37 C under 5 % CO2.
Protein expression and purification
Codon-optimized synthetic human L1 genes encoding
either an ORF1p or ORF2p were synthesized and assem-
bled commercially (GeneART, Regensburg). The sequen-
ces encoding ORF1p and ORF2p were cloned separately
into the BamHI–XhoI sites of pGEX-4T-1 (GE Healthcare)
and the NdeI–XhoI sites of pET32b (Novagen) to create
fusion proteins of GST-ORF1p and 6xHis-ORF2p. These
constructs were transformed into the E. coli strain BL21-
CodonPlus (Stratagene) for the expressions of fusion pro-
teins. The GST-ORF1p purification was performed using
Glutathione HiCap column (Qiagen) and the GST tag was
removed from the fusion protein by thrombin digestion. To
purify the 6xHis-ORF2p, the Ni–NTA affinity column
(Invitrogen) was used as described in the user manual. The
6xHis tag was removed by thrombin digestion. New Zea-
land rabbits were immunized with the purified ORF1p and
ORF2p commercially by IMVS, Australia. Antibodies
were selectively enriched and purified by two steps: the
IgG fractions of antibodies were selectively isolated by
saturated ammonium sulfate precipitation (Pierce), fol-
lowed by antigen-specific affinity purification. The affinity-
purified ORF1p and ORF2p were covalently linked to
N-hydroxysuccinimide (NHS)-activated HiTrap columns
(GE Healthcare), and the column washing and elution of
antibodies were performed according to the supplier’s
instructions.
Validation of antibodies
The construction of the EBNA1-based L1RP expression
vector has been described previously [19]. HeLa cells
(*2 9 105) were transfected with 1 lg of L1RP vector
using Lipofectamine-2000 (Invitrogen). At 36 h after
transfection, the L1RP transfected cells were enriched by
growing in 200 lg/ml hygromycin for 10 days. After
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eliminating untransfected cells, cells were fixed in 4 %
formaldehyde for 15 min and permeabilized in PBS/1 %
BSA/0.25 % Triton X-100 for 10 min, and then blocked
in PBS/1 % BSA for 1 h. Cells were incubated overnight
at 4 C with affinity-purified anti-ORF1p or anti-ORF2p
antibodies (1:60, 1:80 dilutions, respectively). Bound
antibodies were visualized using Texas Red or FITC-
labeled secondary antibodies (Jackson Immunoresearch).
Between steps, cells were washed with PBS/1 % BSA.
Nuclei were stained with 0.5 lg/ml 40,6-diamidino-2-phe-
nylindole (DAPI). The images were photographed using an
Olympus IX81 fluorescence microscope and overlaid using
Adobe Photoshop. For immunofluorescence analysis of
cancer cell lines, cells were grown on glass coverslips in a
12-well plate at a density of 1 9 103 cells per well. Cells
were stained with antibodies and visualized as described
above. The specificity of the antibodies was further con-
firmed by western blotting of whole-cell lysates.
Western blot analysis
Cell lysates were prepared using MPER reagent (Pierce),
according to the manufacturer’s instructions. Protein sam-
ples were separated using a 4–12 % Bis–Tris ployacryla-
mide gel (Invitrogen) and transferred onto Nylon
membranes (GE Healthcare). Western blot analyses were
performed with anti-ORF1p and anti-ORF2p antibodies
at 1:2,000 and 1: 3,000 dilutions, respectively, followed
by the addition of HRP-conjugated secondary antibodies
(Dako Cytomation). The resulting signals were visualized
using the ECL chemiluminescence system (Pierce). To
confirm protein normalization, the membranes were strip-
ped and reprobed with a-tubulin antibodies (Sigma).
Patients and tumor samples
Formalin-fixed paraffin-embedded postsurgical breast
specimens were retrieved from the archival material in our
department, following ethics approval by the ACT Health
Human Research Ethics Committee (no. ETH.8/09.789).
These included blocks from 160 randomly selected patients
with breast cancer diagnosed between 1997 and 2010 with
a mean follow-up of 10.7 years (range 1–14 years). This
included 95 patients with invasive cancers (30 grade I, 35
grade II, and 30 grade III) and 25 DCIS (9 low, 8 inter-
mediate, and 8 high grades). Patient demographics, disease
pathology, hormone receptor status and treatment infor-
mation on these patients were obtained from the Australian
Capital Territory and South East New South Wales Breast
Cancer Treatment Group (ACT & SE NSW BCTG) data-
base. Patients on this database had given informed consent
for these details to be recorded and their disease status to be
followed annually [20]. Patients were excluded if they were
male, had bilateral disease, or had neoadjuvant treatment.
We also retrieved blocks of 15 normal breast tissues
specimens from women who had reduction mammoplasty.
For prognostic evaluation, the following patients’ clinico-
pathologic features were included into the analysis: patient
age (B50 vs. [50 years), tumor size (B20 vs. [20 mm),
tumor type, histologic grade (1 vs. 2 vs. 3), and tumor stage
including lymph node metastases, menopausal status, and
hormone receptor status. The outcomes examined were
breast cancer recurrence rate, overall survival from the
time of primary surgery, breast cancer-specific survival,
and aggregate survival from other causes.
Immunohistochemistry
Immunohistochemistry was performed on the Bond auto-
mated system (Vision Biosystem), following a standard
protocol. In brief, 5-lm tissue sections were dewaxed,
rehydrated through graded alcohol, and stained separately
with anti-ORF1p and anti-ORF2p antibodies. We used heat
retrieval for 28 min at a pH of 8.0. The chromogen Fast
Red (Leica Biosystems) and the DAKO Envision kit were
used to amplify and visualize the signals. Hematoxylin
counterstaining will allow the visualization of cell nuclei.
In each run, a positive and a negative isotype-matched
control were included on each slide to ensure that there is
no false-positive staining. In addition, the normal breast
HMEC and breast cancer T47D cell lines were used as an
additional negative and positive control, respectively.
ORF1p and ORF2p expression was evaluated separately
according to the degree and the proportion of staining
regardless of location. Tumor having no staining or stain-
ing in less than 10 % of tumor cells is considered as neg-
ative expression.
Immunohistochemical scoring
Cytoplasmic and nuclear expression levels of each ORF1p
and ORF2p were scored individually by one pathologist and
one investigator blinded to clinical parameters, using a
weighted histocore method [21]. The discrimination of normal
and malignant breast tissues was based on morphologic
grounds. For each localization, an assessment was made as the
degree of staining intensity and the percentage of cells stained
with that intensity in the nucleus or in the cytoplasm, which
was graded semiquantitatively to produce an intensity distri-
bution score (IDS), with the maximum score 300 (if 100 %
cells stain strongly positive) and the minimum score 0 (if
100 % cells stain negative). The IDS was calculated as
follows: IDS (maximum score 300) = 1 9 percentage of
weakly stained cells ? 2 9 percentage of moderately stained
cells ? 3 9 percentage of strongly stained cells. Average
IDS values were determined by examination of 10 fields.
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Statistical analysis
Analysis was performed with SPSS, V15.0 software for
windows (SPSS Inc., Chicago). The relationships between
expressions of ORF1p and ORF2p in tumor cells and non-
neoplastic cells were evaluated by Fisher’s exact test and
v2 tests. The same test was used to examine the association
between ORF1p and ORF2p expression with prognostic
factors such as tumor grade, tumor size, nodal status, and
hormone receptor status. Kaplan–Meier survival curves
were constructed, and log-rank test was used to assess
whether nuclear or cytoplasmic expression of ORF1p and
ORF2p had any effect on survival. Multivariate analyses
were performed using the Cox regression model. The
overall survival and the relapse-free survival were calcu-
lated from the date of surgery until the date of death or up
to the last follow-up and the date of the relapse or up to the
last follow-up, respectively. The statistical significance
level was set at p \ 0.05.
Results
Anti-ORF1p and Anti-ORF2p antibodies
To investigate breast cancers for expression of L1 retro-
transposons, we constructed a synthetic L1 gene expressing
either an ORF1p or ORF2p. The codon of gene was syn-
onymously optimized for bacterial expression of full-
length protein with an apparent molecular mass 43-kDa of
ORF1p and 150-kDa of ORF2p (Fig. 1A, B). Antibodies
raised against ORF1p and ORF2p were purified and enri-
ched by saturated ammonium sulfate, followed by antigen-
specific affinity chromatography. These antibodies recog-
nized ORF1p and ORF2p at the expected band sizes of
43 and 150 kDa, respectively (Fig. 1C, lanes 3 and 6). As a
negative control, we used bacterial cell extract because
the bacterial genome does not contain L1 sequences. The
specificity of antibodies was tested using the bacterially
induced expression of the fusion protein tagged with GST-
ORF1p and 6xHis-ORF2p. The fusion proteins, with the
expected sizes of 69 kDa for GST-ORF1p and 150 kDa for
6xHis-tagged ORF2p, were recognized in the induced
bacterial extracts, but not in uninduced extracts (Fig. 1C,
lanes 2 and 5).
To test the antibodies for their ability to detect human
ORF1p and ORF2p, we transfected HeLa cells with an L1
expression vector containing a full-length L1RP retro-
transposon under the control of the CMV promoter [19].
Cells transfected with this vector were initially enriched by
applying antibiotic selection for 10 days. After eliminating
untransfected cells, cell lysates were subjected to western
blot using anti-ORF1p and anti-ORF2p antibodies. In
previous studies, HeLa cells have been shown to express at
least a subset of L1 retrotransposons [22]. Human embry-
onic carcinoma NTera.2D1 cells, which express high levels
of L1 mRNA and the encoded proteins as a result of altered
transcription start sites [23], were used as a positive con-
trol. As shown in Fig. 1D, both ORF1p and ORF2p were
significantly overexpressed in cells transfected with L1RP
vector compared with weak detection of untransfected
cells, which is consistent with previous reports [22, 24].
Next, we performed immunofluorescence assay. Although
untransfected HeLa cells (not shown) showed only a weak
background staining, which may be due to the endogenous
L1 expression [22], the L1RP vector-transfected cells
exhibited strong immunostaining in each cell of the culture.
Notably, both ORF1p and ORF2p displayed high immu-
nofluorescence signals in the cytoplasm of cells (Fig. 1E,
panels a and b). This observation is consistent with previ-
ous reports in which strong expressions of ORF1p and
ORF2p were demonstrated in the cytoplasm of human cell
lines including HeLa [24, 25]. To further confirm that
immunoreactivity was a result of the interaction of the
antibodies with L1 proteins, we performed immunofluo-
rescence assay with antigen-depleted primary antibodies,
which were generated by preabsorption with purified
ORF1p and ORF2p immoblized on Sepharose column.
Except for a weak background, no immunoreactivity was
detected in the antigen-depleted antibodies (Fig. 1E, panels
c and d), suggesting that detected fluorescence signals are a
result of the specific interaction between L1 proteins and
antibodies. Together, these results suggest that the anti-
bodies can recognize human ORF1p and ORF2p with high
specificity.
Expressions of ORF1p and ORF2p in breast cancer cell
lines and tissues
Earlier studies revealed that the level of ORF1p is signif-
icantly elevated in breast cancer cell lines [26, 27]. A
recent study of clinical samples has also shown that
expression of ORF1p is widespread in breast tumors [25],
but the expression levels of ORF2p remain unknown. To
gain insight into L1 expression, we first determined the
ORF1p and ORF2p expression in breast cancer cell lines
by Western blot analysis. Clinicopathologic features of
these cells are summarized in Table S1. Human embryonic
carcinoma NTera.2D1 cells were used as a positive control.
As shown in Fig. 2A, both ORF1p and ORF2p were
overexpressed in all tested breast cancer cell lysates (T47D,
SKBR3, BT-20, MDA-MB-361, MCF-7, Hs578T, MDA-
MB-231, and MDA-MB-436), but not in non-tumorigenic
breast epithelial HMECs or its derivative MCF10A cell
line. Notably, the relative expression levels of ORF1p and
ORF2p were markedly higher in low-invasive cancer cells
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(T47D, SKBR3, and BT20) compared with moderate
(MCF7 and Hs578T)-to-highly invasive breast cancer
(MDA-MB-231, MDA-MB-436) cell lines. The increased
expression of both proteins was further confirmed using
immunohistochemistry and immunofluorescence assay
(Fig. 2B, C). Interestingly, the relative levels of ORF2p
expression were lower in all cell lines compared with
ORF1p. While ORF2p shows weak-to-moderate fluores-
cent staining, ORF1p exhibits high fluorescence signals.
This differential expression is consistent with previous
reports from Eugun et al. [24] who detected differential
levels of ORF2p expression in various fetal and adult tis-
sues. Lower expression of ORF2p compared with ORF1p
was also recently reported in vascular endothelial cells
[28].
To further confirm the expression of ORF1p and
ORF2p, we performed the Western blot analysis of whole
cell lysates from breast tumors and their adjacent normal
Fig. 1 Anti-ORF1p and Anti-ORF2p antibodies specifically recog-
nize L1-encoded proteins. A Structure of a functional human L1
retrotransposon showing the 50-UTR promoter, ORF1- and ORF2-
encoding genes, and the 30 poly-A tail. EN endonuclease, RTase
reverse transcriptase, An poly-A tail. B Recombinant 43-kDa ORF1p
and 150-kDa ORF2p were used for the generation of antibodies.
C Western blot analysis examining the specificity of the generated
anti-ORF1p and anti-ORF2p antibodies. Lanes 1 and 4 were loaded
with 50 lg of bacterial extracts isolated from uninduced cells, and
lanes 2 and 5 loaded with the induced bacterial extracts of 69 kDa
GST-ORF1p (left panel) and 150 kDa 6xHis-ORF2p (right panel)
fusion proteins. No staining was seen in the uninduced bacterial
extracts and detection of the fusion proteins of GST-ORF1p and
6xHis-ORF2p in the induced bacterial extracts. Lanes 3 and 6 were
loaded with 25 ng of 43-kDa ORF1p and 150-kDa ORF2p as positive
controls. D The increased expression levels of ORF1p and ORF2p
were detected by western blotting of the L1RP-transfected HeLa cells.
N.Tera.2D1 cells were used as positive controls. For protein
normalization, a-tubulin was used. E Immunofluorescence detection
of transiently expressed ORF1p and ORF2p in the cytoplasm of HeLa
cells using the anti-ORF1p (panel a) and anti-ORF2p (panel b)
antibodies. Nuclei were stained with DAPI (blue) and ORF1p and
ORF2p (Texas Red). As negative controls, the immunofluoresence
assays were performed on the L1RP-transfected HeLa cells with the
antigen-depleted anti-ORF1p (panel c) and anti-ORF2p (panel d)
antibodies
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tissues from two different patients (Fig. 2D). As expected,
the antibodies failed to detect any protein in extracts from
normal breast tissues even after long exposure of the
western blot. In contrast, high expressions of ORF1p and
ORF2p were readily detectable in extracts from breast
tumor tissues. Together, these results indicate that L1-
encoded ORF1p and ORF2p are markedly overexpressed in
breast cancer cells. Given that the both ORF1p and ORF2p
are required for the process of L1 retrotransposition
activity, which could potentially increase genomic insta-
bility, characterizing the expression patterns of these pro-
teins may possibly serve as one of the factors responsible
for genome instability in these cells.
Subcellular localization of ORF1p and ORF2p in breast
tumor tissues
To evaluate a potential link between expression of ORF1p
and ORF2p and the various stages of breast cancer, we
screened paraffin-embedded breast tumor tissues by
immunohistochemistry (Fig. 3). There was little or no
expression in normal breast tissues (n = 15). In contrast,
both ORF1p and ORF2p were differentially expressed in
the breast tumors, and expressions were higher and more
intense staining in DCIS than in invasive cancers. Table 1
shows the overall presence or the absence of the ORF1p
and ORF2p expression regardless of location.
Fig. 2 Aberrant expression of L1 retrotransposons in breast cancer
cells. A Whole-cell lysates of breast cancer cell lines were analyzed
by western blotting with anti-ORF1p and anti-ORF2p antibodies. As a
loading control, a-tubulin was used. Cell lysates from N.Tera.2D1
were used as positive controls. Both ORF1p and ORF2p specifically
expressed in cancer cell lines but not in non-tumorigenic HMEC and
MCF10A cells. B Cell blocks taken from the normal HMEC, poorly
invasive T47D and highly invasive metastatic MDA-MB-231 cell
lines were stained immunohistochemically using the anti-ORF1p and
anti-ORF2p antibodies. HMEC cells did not stain, but T47D cells
displayed strong cytoplasmic staining, whereas MDA-MB-231 cells
showed moderate-to-strong nuclear staining. The merged panel of
Hematoxylin (nucleus) and ORF1p or ORF2p are shown. Bar
represents 20-lm. C The immunofluorescence analysis of ORF1p
expression. L1-encoded proteins appear to localize in both the
cytoplasm and nucleus of cell lines, although the intensity of staining
varies between them. Nuclei were stained with DAPI (blue) and
ORF1p (green). NTera.2D1 and HMEC cells were used as positive
and negative controls, respectively. D Overexpressions of ORF1p and
ORF2p in breast tumors. Protein extracts from breast tumors (T) and
their adjacent normal breast tissues (N) were isolated from two
different patients and performed western blotting. Using the mixture
of both anti-ORF1p and anti-ORF2p antibodies, the expressions of
ORF1p and ORF2p were detected only in breast tumors. For protein
normalization, a-tubulin was used as a loading control
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Expression pattern of ORF1p and ORF2p was found to
be quite variable, and depending on the tumor subtypes,
they can be detected in the nucleus or the cytoplasm.
Although being nuclear gene, both ORF1p and ORF2p are
exported to the cytoplasm for the formation of a ribonu-
cleoprotein (RNP) intermediate where the proteins are
packaged with their own mRNAs, and then enter into the
nucleus for the L1 retrotransposition activity [29]. A recent
study reported that nuclear localization of ORF1p was
significantly associated with aggressive behavior of cancer
and poor outcome [25]. Thus, to assess both nuclear and
cytoplasmic expressions, we examined the localization of
ORF1p and ORF2p in breast cancer cell lines and the
various stages and grades of patient samples. Consistent
Fig. 3 Immunohistochemistry of ORF1p and ORF2p in patient’s
tumor tissues. Shown is representative immunohistochemistry of
ORF1p (top panel) and ORF2p (bottom panel) expressions. A higher
magnification of insert is shown below. A, D In normal breast; B,
E showing high cytoplasmic expression in DCIS; and C, F both
nuclear and cytoplasmic expressions of ORF1p and ORF2p. Bar
represents 200-lm scale. Hematoxylin (blue) represents the nuclei of
cells and pink highlights ORF1p and ORF2p
Table 1 Differential expression of L1-encoded ORF1p and ORF2p










Normal 15 (100) 0 (0) \0.001 53.6 15 (100) 0 (0) \0.001 48.0
Benign 24 (96) 1 (4) 23 (92) 2 (8)
DCIS 3 (12) 22 (88) 4 (16) 21 (84)
Invasive 39 (41) 56 (59) 38 (40) 57 (60)
Tissues having no staining or staining in less than 10 % of cells are considered as negative expression regardless of location
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with previous reports [30], high cytoplasmic expressions
were detected in non-invasive (luminal subtype) T47D
cells, whereas the invasive (basal subtype) MDA-MB-231
cells exhibited strong nuclear and cytoplasmic stainings
(Fig. 2B). None of the normal HMEC cells was stained
with any protein except for the occasional faint background
staining pattern of which differs considerably from the
staining patterns seen in the T47D and MDA-MB-231 cell
lines.
In breast tumor samples, the staining intensity and the
percentage of cells expressing cytoplasmic and nuclear
staining were determined separately using a weighted his-
tocore method [21]. Expression of ORF1p and ORF2p was
both categorized into three groups: (i) cytoplasmic
expression, weak \29 %, moderate 30–59 %, and high
expression [60 %; (ii) nuclear expression, weak \ 29 %,
moderate 30–59 %, and high [ 60 % (Fig. 4). In DCIS
tumors (n = 25), 88 % and 84 % displayed expression that
ranged from weak to high for ORF1p and ORF2p,
respectively. There was no significant difference between
the pattern of staining between low and high grade DCIS.
Notably, both ORF1p and ORF2p exhibited high cyto-
plasmic expression in 76 % (19 of 25) and 80 % (20 of 25)
of cases, respectively. None of the patients with DCIS
displayed high nuclear expression. In contrast, 59 % and
60 % of invasive cancers (n = 95) showed cytoplasmic
and/or nuclear expression for ORF1p and ORF2p, respec-
tively. Notably, 28 % (27 of 95) and 32 % (30 of 95) of
those invasive cancers showed high nuclear expression for
both ORF1p and ORF2p and the cytoplasmic staining,
respectively, which ranged from weak to moderate was
also found in those cases. No significant correlation was
observed between the nuclear expression and histologic
grades although patients with high nuclear expression of
ORF1p and ORF2p showed higher mitotic counts and
higher nuclear pleomorphism than patients with cytoplas-
mic expression. The association between nuclear and
cytoplasmic expression was significant for both ORF1p
and ORF2p (p = 0.0001). Together, these data suggest that
L1 retrotransposons are differentially expressed in breast
tumors, with the highest expression seen in the cytoplasm
of DCIS, whereas the invasive cancers showed expression
ranging from weak to high in both the cytoplasm and
nucleus of the malignant cells.
Association between ORF1p and ORF2p expression
and clinicopathologic characteristics
Tables 2 and 3 summarize the association between cyto-
plasmic and nuclear expression of both ORF1p and ORF1p
and the different clinical features of the patients with DCIS
and invasive cancers. There was no significant correlation
with cytoplasmic ORF1p and ORF2p expression and the
various stages and grades of the breast tumors. Nuclear
expression was only found in a subpopulation of the
invasive cancers in the range of 28 % for ORF1p and 32 %
Fig. 4 Differential expression
of ORF1p and ORF2p. Boxplots
represent the comparison of
histoscores between
cytoplasmic and nuclear
expression of ORF1p and
ORF2p in breast tumors. This
revealed a significant increase in
the nuclear expression of both
ORF1p and ORF2p in invasive
cancers compared with DCIS
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for ORF2p. Patients with high nuclear ORF1p and ORF2p
expression showed apparent association with the presence
of lymph node metastasis (p \ 0.043) than did patients
with cytoplasmic expression. Although nuclear ORF1p and
ORF2p expression was commonly present in ductal tumors
rather than in lobular tumors, no significant correlation was
observed between the nuclear expression and histologic
grades. Interestingly, nuclear ORF1p and ORF2p, but not
cytoplasmic, was associated with lymph node metastasis
and poorer overall survival (p \ 0.05).
L1 expression was found to be highly associated with
patients whose cancers expressed estrogen (ER) and pro-
gesterone (PR). 95 % ER-positive DCIS and 95 % PR-
positive DCIS exhibited cytoplasmic expression of both
ORF1p and ORF2p. In invasive cancers, 64–69 % of
ER-positive and PR-positive cases showed cytoplasmic
expression. A similar association was also found with
nuclear expression in 35–41 % ER and PR-positive inva-
sive cancers (p \ 0.019). Unexpectedly, we found the
expression of both ORF1p and ORF2p in the cytoplasm
of receptors-negative invasive cancers in the range of
37–41 % (9–10 of the 24 patients) ER-negative and
46–48 % (18–19 of 39) of PR-negative tumors, while the
nuclear expression was found in 8–12 % (2–3 of 24) of ER-
negative and 15–17 % (6–7 of 39) of PR-negative cases.
Interestingly, no significant association was observed
between ORF1p and ORF2p expression and other patho-
logic features such as family history, primary size of
tumors, and vascular invasion.
In the breast, it has been recently reported that nuclear,
but not cytoplasmic ORF1p, is associated with genomic
instability of tumors, which are characterized by aggressive
behavior and poor outcome [25]. In agreement with this
study, no correlation between survival of the patients with
DCIS tumors and cytoplasmic expression of ORF1p and
ORF2p were observed. There were no breast cancer-related
deaths in patients with DCIS tumors. In the case of invasive
cancers, 21 % of patients (20 of 95) died with breast can-
cer. The mean follow-up time for the patients with invasive
cancers was 10.7 years (range 1–14 years). When the
localization of the protein was considered, the 10-year
survival was 50–51.8 % for overall nuclear expression
of ORF1p and ORF2p, while cytoplasmic expression was
75–75.4 %. Analysis of the prognostic significance of
expression using the Kaplan–Meier survival curves showed
that nuclear expression of ORF1p and ORF2p significantly
affected patient outcome (p \ 0.0001), but not the cyto-
plasmic expression (Fig. 5). Although nuclear expression
of ORF1p and ORF2p was significantly associated with
ER- and PR-positive invasive cancers in univariate
analysis, the significance of ER and PR disappeared on
Cox-regression multivariate analysis. In Cox-regression
analysis, nuclear expression of both ORF1p and ORF2p
was significantly associated with poor patient outcomes
(p = 0.027, p = 0.027, respectively), while cytoplasmic
expression was not (Table 4). In patients with high nuclear
ORF1p and ORF2p expression, there was a strong trend for
lymph node metastasis (p = 0.001).
Discussion
Genomic instability is a major driving force of tumori-
genesis that might occur in normal tissues even before
morphologic abnormalities are detectable [31]. Although it
has not been completely resolved whether genomic insta-
bility is a cause or consequence of tumor progression, an
unstable genome can be indicative of a poor prognosis in
cancer patients [1]. The mechanistic pathways that activate
genomic instability are not well understood. The activation
of normally repressed L1 retrotransposon has been impli-
cated in a high frequency of DNA breaks and genomic
Fig. 5 Effects of subcellular localizations on overall patient survival.
Kaplan–Meier analysis performed based on the presence of nuclear or
cytoplasmic ORF1p and ORF2p. A Nuclear localization of both
ORF1p and ORF2p exhibited a significant difference in the overall
survival of patients with invasive cancers. B Cytoplasmic localization
of ORF1p and ORF2p showed no difference in patients’ survival.
p value was calculated by log-rank test
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instability [13, 14]. Several studies have shown that there is
a direct correlation between the severity of cancer and the
loss of DNA methylation at the L1 promoter [32, 33].
However, little is known about the L1-encoded ORF1p and
ORF2p expression. A recent study reported that ORF1p is
expressed in a range of cancer tissues including breast and
that its expressions is correlated with worst patient survival
[25]. However, it remains unclear whether any relationship
exists between the various stages and grades of breast
cancers and the expression level of ORF2p, which is a key
protein involved in creating DNA breaks and inserting
L1 copies into genomic DNA during the process of L1
retrotransposition.
In this study, we investigated the expression of both
ORF1p and ORF2p in a range of breast cancer cell lines
and patient tissues and evaluated whether they could pro-
vide any valuable information for cancer prognosis. In in
vitro cell line studies, overexpression of ORF1p and
ORF2p are found to be colocalized in the cytoplasm of cell
lines suggesting that it may be involved in the assembly of
RNP intermediates before entering into the nucleus to
generate L1 retrotransposition activity [29, 30]. The cyto-
plasmic expression of L1 is not often related to tumor
development, whereas nuclear expression is linked to DNA
breaks and genomic instability. In this article, we describe
additional data derived from clinical breast cancer tissue
samples that support the variation of subcellular localiza-
tion seen in the studies of cell lines. We found that the
expression of ORF1p and ORF2p in the majority of
preinvasive breast cancers (DCIS) was cytoplasmic and not
the nucleus, which was not associated with patient survival,
but precisely how this occurs is not clear. One possible
explanation is that L1 retrotransposons might become
active early in cancer development. This early expression
is in agreement with DNA methylation studies in which
early onset of L1 hypomethylation has been reported to
occur in a number of tumors including breast, colon, and
lung [32, 33]. Certainly, hypomethylation of L1 promoters,
which has been shown to correlate with L1 mRNA
expression in breast cancer cell lines [18, 33], would be
consistent with the expression of ORF1p and ORF2p that
we see in DCIS tumors. While there seem to be some
differences in the levels of ORF1p and ORF2p expression
depending on the grade of DCIS, the number of DCIS cases
was quite small in our studies, and further studies are
required to evaluate this.
It is known that depending on microenvironment and
genetic background, different tumor subtypes express dif-
ferent protein profiles. Our study shows that overall
expression levels of ORF1p and ORF2p were higher in
DCIS in the range of 25–28 % than for invasive cancers. It
suggests that these tumors do not need as much of this
protein once they become invasive. Higher expression
levels of other proteins have also been reported in DCIS
including ER, PR, and Her-2neu receptors [34, 35], sug-
gesting that some tumors express variable levels depending
on which is the critical step(s) in tumorigenesis. Genomic
instability tends to correlate with triple negative (ER/PR/
Her-2neu-receptor negative) breast cancer [36]. However,
our study shows that nuclear ORF1p and ORF2p expres-
sion was found in some cases of ER and PR receptor-
positive breast tumors. Although there is known to be
cross-talks between ER and growth factors and other sig-
naling pathways, we do not really understand the relation
between ER/PR and L1 expression, and so this will require
further investigations.
Expression of both ORF1p and ORF2p in the majority
of the invasive breast cancers we studied was mainly
cytoplasmic while nuclear expression occurs only in a
subpopulation of invasive cancers. Changes in subcellular
localizations of ORF1p and ORF2p from cytoplasm to
nucleus may be a critical step in tumorigenesis. It is known
that certain proteins, as we see in ORF1p and ORF2p,
change their cellular localization during tumor progression.
One well-studied case is ß-catenin which is associated with
tumor progression upon nuclear localization [37]. Our
results showed that nuclear expression of ORF1p and
ORF2p in the invasive cancers and not cytoplasmic, was
associated with poorer survival in patients with a more
aggressive phenotype of lymph node metastasis. This
indicated that different staining locations of ORF1p and
ORF2p may have distinct biologic significances for the
Table 4 Multivariate Cox-regression analysis of cytoplasmic and







Cytoplasm 2.159 0.616–7.545 0.228
Nucleus 0.339 0.13–0.886 0.027
ORF2p
Cytoplasm 0.503 0.141–1.798 0.29
Nucleus 0.239 0.099–0.87 0.027
Age 2.855 0.061–134.132 0.593
Family history 1.32 0.016–110.778 0.902
Menopause 0.383 0.009–16.29 0.616
Size 0.54 0.144–2.021 0.36
Vascular invasion 2.452 0.687–8.754 0.167
ER 1.049 0.199–5.519 0.955
PR 2.499 0.525–11.887 0.25
Histology 1.163 0.137–9.855 0.89
Grade 1.085 0.17–6.905 0.604
Lymph node metastasis 0.182 0.065–0.514 0.001
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metastatic potential of breast cancer, and the result was
similar to a recent study in which nuclear ORF1p was
found to be associated with increased risk of distant
recurrence and poor prognosis [25]. The functional role of
nuclear L1 localization and its relationship with tumor
development has not been elucidated. In the literature,
nuclear L1 expression is linked to genomic instability and
DNA breaks. Sciamanna et al. [38] have shown that the
inhibition of reverse transcriptase activity of ORF2p
reduces cell proliferation and promotes differentiation by
reprogramming gene expression in tumorigenic cell lines.
Recently, it has been postulated that the L1 retrotranspo-
sition activity in the nucleus might interfere with the
transcription machinery of cells, and thereby it may be
involved in the development and progression of cancer
[39]. Thus, identifying the mechanisms by which nuclear
localization of ORF1p and ORF2p occur may help us
understand the consequences of L1 expression in breast
cancer cells.
Conclusion
This study has presented the relationships and relevance
with respect to biologic and clinical usefulness of expres-
sion and subcellular localization of L1-encoded ORF1p
and ORF2p in breast cancer. In this study, we have shown,
first, high cytoplasmic expression of L1 retrotransposon in
the DCIS. In the majority of invasive cancers, L1 expres-
sion is found mainly in the cytoplasm, while nuclear
expression occurs only in a subclass of invasive cancers.
Second, only nuclear expression of ORF1p and ORF2p is
associated with poorer survival in patients with invasive
cancers and it is not related to tumor size and family his-
tory. Third, tumors expressing estrogen or progesterone
receptors are more likely to show L1 expression than that
of receptor negative. This study is the first to observe the
effects of both ORF1p and ORF2p expression in human
breast cancer. Our observations show that considerable
heterogeneity exists in the expression pattern of ORF1p
and ORF2p in breast tumors, which relate to biologic and
clinical differences in overall patient survival. The asso-
ciations found for both cytoplasmic and nuclear expression
of ORF1p and ORF2p suggest that further studies of the
biology and function of L1 retrotransposons are warranted
in breast cancer.
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